n,n-dimethyl-n-hexadecyl-1-octadecylammonium and Local Neoplasm Recurrence

n,n-dimethyl-n-hexadecyl-1-octadecylammonium has been researched along with Local Neoplasm Recurrence in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Bernardo, MCC; Braojo, IMP; Caballero, BB; Carrasco, JM; Fernández, BM; Guerrero, OV; Gutiérrez, ZA; Medina, EAG; Miguel, KL; Montero, YC; Ortiz, MR; Prado, YID; Rodríguez, LEM; Rubio, MC; Torres, KP; Tul, LEA; Varela, IGS	1

Other Studies

1 other study(ies) available for n,n-dimethyl-n-hexadecyl-1-octadecylammonium and Local Neoplasm Recurrence

Article	Year
Neoadjuvant Trastuzumab and Pertuzumab in Combination with Standard Chemotherapy for HER2-Positive Early Breast Cancer: Real-World Practice in Cuba. Cancer treatment and research communications, 2023, Volume: 34 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cuba; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prospective Studies; Receptor, ErbB-2; Trastuzumab	2023

Article

Year

Neoadjuvant Trastuzumab and Pertuzumab in Combination with Standard Chemotherapy for HER2-Positive Early Breast Cancer: Real-World Practice in Cuba.

Cancer treatment and research communications, 2023, Volume: 34

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cuba; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prospective Studies; Receptor, ErbB-2; Trastuzumab

2023